A method of using a self-adjusting stent assembly includes estimating body lumen diameter(s) associated with a portion of a body lumen in which a stent assembly will be placed; determining, based on the estimated diameter(s), target expanded stent diameter(s) of the stent assembly which is to be placed in the portion of the body lumen; selecting the stent assembly for stenting the portion of the body lumen, wherein the stent assembly is configured to: expand from an initial to expanded diameters within a range of expanded diameters; wherein the range of expanded diameters is from about 9 mm to about 5.5 mm; and wherein the target expanded stent diameter(s) is/are within the range of expanded diameters; and apply a chronic radial force to a wall that forms the portion of the lumen, wherein the radial force is less than about 0.33 N/mm.

A delivery endcap assembly is adapted for use with a biliary access device and is adapted to permit a medical device to be delivered through the biliary access device. The delivery endcap assembly includes a securement portion adapted to be releasably securable to a proximal end of the handle after the one or more removable components have been removed from the handle, a tapered portion extending proximally from the securement portion, a rotation hub adapted to be coupled to the securement portion, a valve adapted to be coupled to the rotation hub and a lumen extending through the delivery endcap assembly, wherein the lumen extending through the delivery endcap assembly is adapted to permit a medical device within an introducer sheath to be advanced through the biliary access device.

The present disclosure relates generally to the field of medical devices and establishing fluid communication between body lumens. In particular, the present disclosure relates to devices and methods for placing the muscularis layers of first and second body lumens in contact to establish a long term or permanent open flow or access passage therebetween.

The present disclosure provides an endoprosthesis where a preferably polymeric coating has a number of surface features such as protrusions or textures that are arranged in a micropattern. The endoprosthesis optionally has an expanded state and a contracted state, and in some cases includes a stent with a polymeric coating attached to an outer surface of the stent. The stent may have an inner surface defining a lumen, an outer surface, and a stent thickness defined between the inner surface and outer surface. The stent may comprise a plurality of surface textures extending from the stent surfaces, wherein the textures are arranged in a macropattern.

The present disclosure relates to the field of endoscopy. Specifically, the present disclosure relates to systems and methods which allow the distal portion of a catheter to be visualized within the body using a colored marker and one or more secondary markers. In particular, the present disclosure relates to systems and methods which indicate when a medical device is properly positioned for deployment within a body lumen.

A lumen-apposing access system may include a catheter and a cauterization tip. The cauterization tip may include a biasing member and a cautery element. The cauterization tip may move relative to the catheter between a first position in which the cautery element is electrically inactive, and a second position in which the cautery element is electrically active. The biasing member biases the cautery element in the first position.

The present disclosure relates generally to the field of devices and procedures for placement of a medical device between adjacent tissue structures. In particular, the present disclosure relates to systems and methods for percutaneous placement of a drainage stent between the gallbladder and gastric lumen (e.g., cholecystogastrostomy), or gallbladder and duodenum (cholecystoduodenostomy).

Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

A pancreatic stent includes a main body convertible between a compressed configuration for delivery and an expanded configuration once deployed, the main body including an inner surface defining a stent lumen and an outer surface. A plurality of drainage features are formed within the outer surface of the main body, the plurality of drainage features permitting placement of the pancreatic stent within a patient's pancreas without blocking side branches of the pancreas.

An endoprosthesis may include an expandable framework including an anchoring portion and a body portion extending axially from the anchoring portion, the body portion having a plurality of body cells; and a polymeric cover disposed on at least a portion of the expandable framework. The anchoring portion includes a first transverse flange and a second transverse flange proximate the first transverse flange, the first and second transverse flanges being configured to secure the anchoring portion at an orifice of a body lumen. The body portion includes a window through a side of the body portion, the window occupying space equivalent to at least two of the plurality of body cells. The window is devoid of the polymeric cover and any other structure within a perimeter of the window.